Abstract:Developing novel therapeutics and diagnostic tools based upon an understanding of neuroplasticity is critical in order to improve the treatment and ultimately the prevention of a broad range of nervous system disorders. In the case of mood disorders, such as major depressive disorder (MDD) and bipolar disorder (BPD), where diagnoses are based solely on nosology rather than pathophysiology, there exists a clear unmet medical need to advance our understanding of the underlying molecular mechanisms and to develop fundamentally new mechanism experimental medicines with improved efficacy. In this context, recent preclinical molecular, cellular, and behavioral findings have begun to reveal the importance of epigenetic mechanisms that alter chromatin structure and dynamically regulate patterns of gene expression that may play a critical role in the pathophysiology of mood disorders. Here, we will review recent advances involving the use of animal models in combination with genetic and pharmacological probes to dissect the underlying molecular mechanisms and neurobiological consequence of targeting this chromatin-mediated neuroplasticity. We discuss evidence for the direct and indirect effects of mood stabilizers, antidepressants, and antipsychotics, among their many other effects, on chromatin-modifying enzymes and on the epigenetic state of defined genomic loci, in defined cell types and in specific regions of the brain. These data, as well as findings from patient-derived tissue, have also begun to reveal alterations of epigenetic mechanisms in the pathophysiology and treatment of mood disorders. We summarize growing evidence supporting the notion that selectively targeting chromatin-modifying complexes, including those containing histone deacetylases (HDACs), provides a means to reversibly alter the acetylation state of neuronal chromatin and beneficially impact neuronal activity-regulated gene transcription and mood-related behaviors. Looking beyond current knowledge, we discuss how high-resolution, whole-genome methodologies, such as RNA-sequencing (RNA-Seq) for transcriptome analysis and chromatin immunoprecipitation-sequencing (ChIP-Seq) for analyzing genome-wide occupancy of chromatin-associated factors, are beginning to provide an unprecedented view of both specific genomic loci as well as global properties of chromatin in the nervous system. These methodologies when applied to the characterization of model systems, including those of patient-derived induced pluripotent cell (iPSC) and induced neurons (iNs), will greatly shape our understanding of epigenetic mechanisms and the impact of genetic variation on the regulatory regions of the human genome that can affect neuroplasticity. Finally, we point out critical unanswered questions and areas where additional data are needed in order to better understand the potential to target mechanisms of chromatin-mediated neuroplasticity for novel treatments of mood and other psychiatric disorders.

Epigenetic mechanisms of stress and depression.

Epigenetics in depression and gut-brain axis: A molecular crosstalk

Stress, epigenetics and depression: A systematic review

Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential

Epigenetic alterations in depression and antidepressant treatment

Epigenetic Mechanisms in the Neurodevelopmental Theory of Depression

Epigenetic signaling in psychiatric disorders: stress and depression

Epigenetic Mechanisms in Depression: Implications for Pathogenesis and Treatment.

Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: the 5-HT1A receptor gene as a paradigm

Looking beyond the DNA sequence: the relevance of DNA methylation processes for the stress-diathesis model of depression

Stress, genetics and epigenetic effects on the neurobiology of suicidal behavior and depression

Effect of Early Life Stress on the Epigenetic Profiles in Depression

Depressive disorder and antidepressants from an epigenetic point of view

Epigenetic mechanisms in mood disorders: targeting neuroplasticity

Epigenetic modulation of inflammation and synaptic plasticity promotes resilience against stress in mice

Epigenetics and Depression: An Update

Advance in Stress for Depressive Disorder.

Epigenetics and depressive disorders: a review of current progress and future directions

Epigenetic Modulation: Research Progress on Histone Acetylation Levels in Major Depressive Disorders

Epigenetic molecular underpinnings of brain structural-functional connectivity decoupling in patients with major depressive disorder

Genetics and epigenetics of the SLC6A4 gene in depression